Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long-Term?

Cortese S, Swanson JM, Coghill D.

J Am Acad Child Adolesc Psychiatry. 2019 Jun 26. pii: S0890-8567(19)30418-6. doi: 10.1016/j.jaac.2019.04.029. [Epub ahead of print] No abstract available.

PMID:
31254608
2.

Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials.

Wong ICK, Banaschewski T, Buitelaar J, Cortese S, Döpfner M, Simonoff E, Coghill D; European ADHD Guidelines Group.

Lancet Psychiatry. 2019 Jun;6(6):528-537. doi: 10.1016/S2215-0366(19)30096-3. Review.

PMID:
31122482
3.

Development and psychometric properties of the "Suicidality: Treatment Occurring in Paediatrics (STOP) Risk and Resilience Factors Scales" in adolescents.

Rodríguez-Quiroga A, Flamarique I, Castro-Fornieles J, Lievesley K, Buitelaar JK, Coghill D, Díaz-Caneja CM, Dittmann RW, Gupta A, Hoekstra PJ, Kehrmann L, Llorente C, Purper-Ouakil D, Schulze UME, Zuddas A, Sala R, Singh J, Fiori F, Arango C, Santosh P; STOP Consortium.

Eur Child Adolesc Psychiatry. 2019 May 3. doi: 10.1007/s00787-019-01328-2. [Epub ahead of print]

PMID:
31054125
4.

Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples.

Hoogman M, Muetzel R, Guimaraes JP, Shumskaya E, Mennes M, Zwiers MP, Jahanshad N, Sudre G, Wolfers T, Earl EA, Soliva Vila JC, Vives-Gilabert Y, Khadka S, Novotny SE, Hartman CA, Heslenfeld DJ, Schweren LJS, Ambrosino S, Oranje B, de Zeeuw P, Chaim-Avancini TM, Rosa PGP, Zanetti MV, Malpas CB, Kohls G, von Polier GG, Seitz J, Biederman J, Doyle AE, Dale AM, van Erp TGM, Epstein JN, Jernigan TL, Baur-Streubel R, Ziegler GC, Zierhut KC, Schrantee A, Høvik MF, Lundervold AJ, Kelly C, McCarthy H, Skokauskas N, O'Gorman Tuura RL, Calvo A, Lera-Miguel S, Nicolau R, Chantiluke KC, Christakou A, Vance A, Cercignani M, Gabel MC, Asherson P, Baumeister S, Brandeis D, Hohmann S, Bramati IE, Tovar-Moll F, Fallgatter AJ, Kardatzki B, Schwarz L, Anikin A, Baranov A, Gogberashvili T, Kapilushniy D, Solovieva A, El Marroun H, White T, Karkashadze G, Namazova-Baranova L, Ethofer T, Mattos P, Banaschewski T, Coghill D, Plessen KJ, Kuntsi J, Mehta MA, Paloyelis Y, Harrison NA, Bellgrove MA, Silk TJ, Cubillo AI, Rubia K, Lazaro L, Brem S, Walitza S, Frodl T, Zentis M, Castellanos FX, Yoncheva YN, Haavik J, Reneman L, Conzelmann A, Lesch KP, Pauli P, Reif A, Tamm L, Konrad K, Oberwelland Weiss E, Busatto GF, Louza MR, Durston S, Hoekstra PJ, Oosterlaan J, Stevens MC, Ramos-Quiroga JA, Vilarroya O, Fair DA, Nigg JT, Thompson PM, Buitelaar JK, Faraone SV, Shaw P, Tiemeier H, Bralten J, Franke B.

Am J Psychiatry. 2019 Jul 1;176(7):531-542. doi: 10.1176/appi.ajp.2019.18091033. Epub 2019 Apr 24.

PMID:
31014101
5.

Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy.

Schneider G, Banaschewski T, Feldman BL, Gustafsson PA, Murphy B, Reynolds M, Coghill DR, Spalding WM.

J Child Adolesc Psychopharmacol. 2019 May;29(4):285-304. doi: 10.1089/cap.2018.0132. Epub 2019 Apr 3.

6.

Mental health difficulties across childhood and mental health service use: findings from a longitudinal population-based study.

Mulraney M, Hiscock H, Sciberras E, Coghill D, Sawyer M.

Br J Psychiatry. 2019 Feb 27:1-6. doi: 10.1192/bjp.2019.32. [Epub ahead of print]

PMID:
30810103
7.

Reply to Leon et al.

Cortese S, Coghill D.

Evid Based Ment Health. 2019 Feb;22(1):e2. doi: 10.1136/ebmental-2019-300081. No abstract available.

PMID:
30692143
8.

Psychosocial risk factors for suicidality in children and adolescents.

Carballo JJ, Llorente C, Kehrmann L, Flamarique I, Zuddas A, Purper-Ouakil D, Hoekstra PJ, Coghill D, Schulze UME, Dittmann RW, Buitelaar JK, Castro-Fornieles J, Lievesley K, Santosh P, Arango C; STOP Consortium.

Eur Child Adolesc Psychiatry. 2019 Jan 25. doi: 10.1007/s00787-018-01270-9. [Epub ahead of print] Review.

PMID:
30684089
9.

Validity and reliability of the Dundee difficult times of the day scale in Chinese children and adolescents with attention-deficit/hyperactivity disorder.

Du Y, Zheng Y, Ke X, Su L, Coghill D, Chen Y, Zhang Y, Yuan Z, Cheng Y, Chen W.

J Comp Eff Res. 2019 Jan;8(1):33-44. doi: 10.2217/cer-2018-0091. Epub 2018 Nov 23.

10.

Unbalanced risk-benefit analysis of ADHD drugs - Authors' reply.

Cipriani A, Adamo N, Giovane CD, Coghill D, Banaschewski T, Hollis C, Zuddas A, Simonoff E, Cortese S.

Lancet Psychiatry. 2018 Nov;5(11):871-873. doi: 10.1016/S2215-0366(18)30396-1. Epub 2018 Oct 26. No abstract available.

PMID:
30401441
11.

Can depression be prevented in children and adolescents?

Wiggins A, Coghill D.

J Paediatr Child Health. 2018 Dec;54(12):1386-1388. doi: 10.1111/jpc.14267. Epub 2018 Oct 30. No abstract available.

PMID:
30378216
12.

Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS).

McCarthy S, Neubert A, Man KKC, Banaschewski T, Buitelaar J, Carucci S, Coghill D, Danckaerts M, Falissard B, Garas P, Häge A, Hollis C, Inglis S, Kovshoff H, Liddle E, Mechler K, Nagy P, Rosenthal E, Schlack R, Sonuga-Barke E, Zuddas A, Wong ICK.

BMC Psychiatry. 2018 Oct 11;18(1):327. doi: 10.1186/s12888-018-1884-7.

13.

Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward.

Cortese S, Coghill D.

Evid Based Ment Health. 2018 Nov;21(4):173-176. doi: 10.1136/ebmental-2018-300050. Epub 2018 Oct 9. Review.

PMID:
30301823
14.

Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.

Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell G, Crystal S, Furu K, KaoYang YH, Karlstad Ø, Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Pottegård A, Pratt NL, Roughead EE, Macias Saint-Gerons D, Stürmer T, Su CC, Zoega H, Sturkenbroom MCJM, Chan EW, Coghill D, Ip P, Wong ICK.

Lancet Psychiatry. 2018 Oct;5(10):824-835. doi: 10.1016/S2215-0366(18)30293-1. Epub 2018 Sep 13.

PMID:
30220514
15.

Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial.

Pride NA, Barton B, Hutchins P, Coghill DR, Korgaonkar MS, Hearps SJC, Rouel M, Malarbi S, North KN, Payne JM.

BMJ Open. 2018 Aug 30;8(8):e021800. doi: 10.1136/bmjopen-2018-021800.

16.

Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.

Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A.

Lancet Psychiatry. 2018 Sep;5(9):727-738. doi: 10.1016/S2215-0366(18)30269-4. Epub 2018 Aug 7.

17.

Treatment strategies for ADHD: an evidence-based guide to select optimal treatment.

Caye A, Swanson JM, Coghill D, Rohde LA.

Mol Psychiatry. 2019 Mar;24(3):390-408. doi: 10.1038/s41380-018-0116-3. Epub 2018 Jun 28. Review.

PMID:
29955166
18.

Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

Banaschewski T, Johnson M, Nagy P, Otero IH, Soutullo CA, Yan B, Zuddas A, Coghill DR.

CNS Drugs. 2018 May;32(5):455-467. doi: 10.1007/s40263-018-0514-8.

19.

Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents.

Zhou X, Liu L, Lan X, Cohen D, Zhang Y, Ravindran AV, Yuan S, Zheng P, Coghill D, Yang L, Hetrick SE, Jiang X, Benoliel JJ, Cipriani A, Xie P.

Mol Psychiatry. 2018 Apr 20. doi: 10.1038/s41380-018-0047-z. [Epub ahead of print]

PMID:
29679072
20.

An international clinical study of ability and disability in ADHD using the WHO-ICF framework.

Mahdi S, Ronzano N, Knüppel A, Dias JC, Albdah A, Chien-Ho L, Almodayfer O, Bluschke A, Karande S, Huang HL, Christiansen H, Granlund M, de Vries PJ, Coghill D, Tannock R, Rohde L, Bölte S.

Eur Child Adolesc Psychiatry. 2018 Oct;27(10):1305-1319. doi: 10.1007/s00787-018-1124-1. Epub 2018 Feb 17.

PMID:
29455340
21.

Standardised assessment of functioning in ADHD: consensus on the ICF Core Sets for ADHD.

Bölte S, Mahdi S, Coghill D, Gau SS, Granlund M, Holtmann M, Karande S, Levy F, Rohde LA, Segerer W, de Vries PJ, Selb M.

Eur Child Adolesc Psychiatry. 2018 Oct;27(10):1261-1281. doi: 10.1007/s00787-018-1119-y. Epub 2018 Feb 12.

PMID:
29435654
22.

Developing the Symptoms and Functional Impairment Rating Scale: A Multi-Dimensional ADHD Scale.

Du Y, Li M, Jiang W, Li Y, Coghill DR.

Psychiatry Investig. 2018 Jan;15(1):13-23. doi: 10.4306/pi.2018.15.1.13. Epub 2018 Jan 16.

23.

Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate.

Coghill DR, Banaschewski T, Bliss C, Robertson B, Zuddas A.

CNS Drugs. 2018 Jan;32(1):85-95. doi: 10.1007/s40263-017-0487-z.

24.

Barriers to medication entitlements after diagnosis of ADHD - Authors' reply.

Sayal K, Prasad V, Daley D, Ford T, Coghill D.

Lancet Psychiatry. 2018 Jan;5(1):19-20. doi: 10.1016/S2215-0366(17)30487-X. No abstract available.

PMID:
29277206
25.

Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: A systematic review and meta-analysis.

Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, Lau WCY, Schuemie MJ, Sturkenboom MCJM, Wong ICK.

Neurosci Biobehav Rev. 2018 Mar;86:1-11. doi: 10.1016/j.neubiorev.2017.12.007. Epub 2017 Dec 13.

PMID:
29247762
26.

A comparison of the clinical effectiveness and cost of specialised individually delivered parent training for preschool attention-deficit/hyperactivity disorder and a generic, group-based programme: a multi-centre, randomised controlled trial of the New Forest Parenting Programme versus Incredible Years.

Sonuga-Barke EJS, Barton J, Daley D, Hutchings J, Maishman T, Raftery J, Stanton L, Laver-Bradbury C, Chorozoglou M, Coghill D, Little L, Ruddock M, Radford M, Yao GL, Lee L, Gould L, Shipway L, Markomichali P, McGuirk J, Lowe M, Perez E, Lockwood J, Thompson MJJ.

Eur Child Adolesc Psychiatry. 2018 Jun;27(6):797-809. doi: 10.1007/s00787-017-1054-3. Epub 2017 Oct 30.

27.

Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder.

Daley D, Van Der Oord S, Ferrin M, Cortese S, Danckaerts M, Doepfner M, Van den Hoofdakker BJ, Coghill D, Thompson M, Asherson P, Banaschewski T, Brandeis D, Buitelaar J, Dittmann RW, Hollis C, Holtmann M, Konofal E, Lecendreux M, Rothenberger A, Santosh P, Simonoff E, Soutullo C, Steinhausen HC, Stringaris A, Taylor E, Wong ICK, Zuddas A, Sonuga-Barke EJ.

J Child Psychol Psychiatry. 2018 Sep;59(9):932-947. doi: 10.1111/jcpp.12825. Epub 2017 Oct 30. Review.

PMID:
29083042
28.

ADHD in children and young people: prevalence, care pathways, and service provision.

Sayal K, Prasad V, Daley D, Ford T, Coghill D.

Lancet Psychiatry. 2018 Feb;5(2):175-186. doi: 10.1016/S2215-0366(17)30167-0. Epub 2017 Oct 9. Review.

PMID:
29033005
29.

Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD.

Coghill DR, Joseph A, Sikirica V, Kosinski M, Bliss C, Huss M.

J Atten Disord. 2017 Aug 1:1087054717723984. doi: 10.1177/1087054717723984. [Epub ahead of print]

PMID:
28836895
30.

Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis.

Zhou X, Cipriani A, Zhang Y, Cuijpers P, Hetrick SE, Weisz JR, Pu J, Giovane CD, Furukawa TA, Barth J, Coghill D, Leucht S, Yang L, Ravindran AV, Xie P.

BMJ Open. 2017 Aug 11;7(8):e016608. doi: 10.1136/bmjopen-2017-016608.

31.

Association of Risk of Suicide Attempts With Methylphenidate Treatment.

Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Schuemie MJ, Sturkenboom MCJM, Sonuga-Barke E, Buitelaar J, Carucci S, Zuddas A, Kovshoff H, Garas P, Nagy P, Inglis SK, Konrad K, Häge A, Rosenthal E, Wong ICK.

JAMA Psychiatry. 2017 Oct 1;74(10):1048-1055. doi: 10.1001/jamapsychiatry.2017.2183.

32.

Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.

Coghill DR, Banaschewski T, Nagy P, Otero IH, Soutullo C, Yan B, Caballero B, Zuddas A.

CNS Drugs. 2017 Jul;31(7):625-638. doi: 10.1007/s40263-017-0443-y.

33.

Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study.

Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, Lau WCY, Schuemie MJ, Sturkenboom MCJM, Wong ICK.

BMJ. 2017 May 31;357:j2350. doi: 10.1136/bmj.j2350.

34.

ADHD Symptoms and Quality of Life Across a 12-Month Period in Children With ADHD: A Longitudinal Study.

Mulraney M, Giallo R, Sciberras E, Lycett K, Mensah F, Coghill D.

J Atten Disord. 2017 May 1:1087054717707046. doi: 10.1177/1087054717707046. [Epub ahead of print]

PMID:
28490210
35.

Personalized Medication Response Prediction for Attention-Deficit Hyperactivity Disorder: Learning in the Model Space vs. Learning in the Data Space.

Wong HK, Tiffin PA, Chappell MJ, Nichols TE, Welsh PR, Doyle OM, Lopez-Kolkovska BC, Inglis SK, Coghill D, Shen Y, Tiño P.

Front Physiol. 2017 Apr 11;8:199. doi: 10.3389/fphys.2017.00199. eCollection 2017.

36.

Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder.

Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A.

Eur Child Adolesc Psychiatry. 2017 Nov;26(11):1283-1307. doi: 10.1007/s00787-017-0986-y. Epub 2017 Apr 20. Review.

37.

Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.

Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK; ADDUCE consortium.

CNS Drugs. 2017 Mar;31(3):199-215. doi: 10.1007/s40263-017-0410-7. Review.

38.

What are the benefits of methylphenidate as a treatment for children and adolescents with attention-deficit/hyperactivity disorder?

Gerlach M, Banaschewski T, Coghill D, Rohde LA, Romanos M.

Atten Defic Hyperact Disord. 2017 Mar;9(1):1-3. doi: 10.1007/s12402-017-0220-2. No abstract available.

PMID:
28168407
39.

The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication?

Balia C, Carucci S, Coghill D, Zuddas A.

Neurosci Biobehav Rev. 2018 Aug;91:218-238. doi: 10.1016/j.neubiorev.2017.01.024. Epub 2017 Jan 27.

PMID:
28137460
40.

Prenatal Risk Factors and the Etiology of ADHD-Review of Existing Evidence.

Sciberras E, Mulraney M, Silva D, Coghill D.

Curr Psychiatry Rep. 2017 Jan;19(1):1. doi: 10.1007/s11920-017-0753-2. Review.

PMID:
28091799
41.

Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.

Cortese S, Adamo N, Mohr-Jensen C, Hayes AJ, Bhatti S, Carucci S, Del Giovane C, Atkinson LZ, Banaschewski T, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A, Coghill D; European ADHD Guidelines Group (EAGG).

BMJ Open. 2017 Jan 10;7(1):e013967. doi: 10.1136/bmjopen-2016-013967.

42.

Organisation of services for managing ADHD.

Coghill DR.

Epidemiol Psychiatr Sci. 2017 Oct;26(5):453-458. doi: 10.1017/S2045796016000937. Epub 2016 Dec 22.

PMID:
28004618
43.

A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder.

Nagy B, Setyawan J, Coghill D, Soroncz-Szabó T, Kaló Z, Doshi JA.

Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):283-292. doi: 10.1080/14737167.2017.1271325. Epub 2016 Dec 26. Review.

PMID:
27967261
44.

Development and psychometric properties of the Suicidality: Treatment Occurring in Paediatrics (STOP) Suicidality Assessment Scale (STOP-SAS) in children and adolescents.

Flamarique I, Santosh P, Zuddas A, Arango C, Purper-Ouakil D, Hoekstra PJ, Coghill D, Schulze U, Dittmann RW, Buitelaar JK, Lievesley K, Frongia R, Llorente C, Méndez I, Sala R, Fiori F, Castro-Fornieles J; STOP consortium.

BMC Pediatr. 2016 Dec 13;16(1):213.

45.

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater.

Banaschewski T, Buitelaar J, Chui CS, Coghill D, Cortese S, Simonoff E, Wong IC.

Evid Based Ment Health. 2016 Nov;19(4):97-99. doi: 10.1136/eb-2016-102461. Epub 2016 Oct 6.

PMID:
27935807
46.

Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system.

Man KK, Coghill D, Chan EW, Lau WC, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Wong IC.

Transl Psychiatry. 2016 Nov 15;6(11):e956. doi: 10.1038/tp.2016.216.

47.

The impact of ADHD on the health and well-being of ADHD children and their siblings.

Peasgood T, Bhardwaj A, Biggs K, Brazier JE, Coghill D, Cooper CL, Daley D, De Silva C, Harpin V, Hodgkins P, Nadkarni A, Setyawan J, Sonuga-Barke EJ.

Eur Child Adolesc Psychiatry. 2016 Nov;25(11):1217-1231. Epub 2016 Apr 1.

48.

Annual Research Review: Quality of life and childhood mental and behavioural disorders - a critical review of the research.

Jonsson U, Alaie I, Löfgren Wilteus A, Zander E, Marschik PB, Coghill D, Bölte S.

J Child Psychol Psychiatry. 2017 Apr;58(4):439-469. doi: 10.1111/jcpp.12645. Epub 2016 Oct 6. Review.

PMID:
27709604
49.

Check and Double Check - the Cochrane review by Storebo et al. (2015) is indeed flawed.

Romanos M, Coghill D, Gerlach M, Becker K, Holtmann M, Döpfner M, Banaschewski T.

Z Kinder Jugendpsychiatr Psychother. 2016 Sep;44(5):336-337. No abstract available.

50.

Recommendations for the transition of patients with ADHD from child to adult healthcare services: a consensus statement from the UK adult ADHD network.

Young S, Adamou M, Asherson P, Coghill D, Colley B, Gudjonsson G, Hollis C, McCarthy J, Müller U, Paul M, Pitts M, Arif M.

BMC Psychiatry. 2016 Aug 26;16:301. doi: 10.1186/s12888-016-1013-4.

Supplemental Content

Loading ...
Support Center